KBC Group NV Has $1.04 Million Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

KBC Group NV lowered its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 69.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,674 shares of the company's stock after selling 224,828 shares during the period. KBC Group NV's holdings in Elanco Animal Health were worth $1,036,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ELAN. CoreCap Advisors LLC acquired a new position in Elanco Animal Health during the 4th quarter worth about $29,000. Parallel Advisors LLC lifted its position in Elanco Animal Health by 92.2% during the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after buying an additional 1,852 shares in the last quarter. NBC Securities Inc. acquired a new position in Elanco Animal Health during the 1st quarter worth about $40,000. Jones Financial Companies Lllp lifted its position in Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after buying an additional 2,059 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in Elanco Animal Health by 65.9% during the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock worth $46,000 after buying an additional 1,740 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Trading Down 0.9%

Shares of ELAN stock traded down $0.14 on Monday, reaching $14.51. The company had a trading volume of 910,566 shares, compared to its average volume of 5,071,667. The company has a current ratio of 2.71, a quick ratio of 1.46 and a debt-to-equity ratio of 0.68. The stock has a market cap of $7.20 billion, a PE ratio of 19.68, a PEG ratio of 2.86 and a beta of 1.67. The company has a 50-day moving average of $12.93 and a 200-day moving average of $11.59. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $15.78.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.06. The company had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.17 billion. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. Elanco Animal Health's revenue was down 1.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.34 EPS. On average, equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ELAN. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Finally, Stifel Nicolaus boosted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a report on Wednesday, July 2nd. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.